Humacyte has launched a Phase 2a clinical trial testing its bioengineered coronary tissue engineered vessel (CTEV) in patients needing coronary artery bypass grafting (CABG). This off-the-shelf vessel aims to replace the need for harvesting veins from patients, which can cause complications and have limited durability. The FDA approved the trial in July 2026, and it will assess safety and effectiveness in 10 patients, with follow-up for up to three years. Successful results could transform coronary bypass surgery by providing a ready-made, regenerative vessel option.
Humacyte's first-in-human coronary bypass study provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced US health-sector stocks, 121 rose and 18 fell today. Notable movers include ABEO at USD 3.65 with a 1-day change of -12.47% and a typical hold time of 28 days, IMVT at USD 33.50 up 9.73% with a 17-day hold, and INO at USD 1.32 up 8.64% with a 41-day hold.
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
Credit Agricole Toulouse 31 disclosed its weekly transactions involving the buyback of its cooperative investment certificates (CCI) from November 2 to November 6, 2026. The bank repurchased varying volumes daily, with prices ranging around 98.82 to ...
